CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed ovarian epithelial, primary peritoneal serous, or fallopian tube cancer
• * Recurrent or persistent disease
• * Elevated CA 125, defined as ≥ 40 U/mL on 2 separate consecutive measurements taken ≥ 1 week apart
• No definitive disease OR small-volume disease (≤ 2 cm by spiral or conventional CT scan or clinical exam)
• Asymptomatic disease
• PATIENT CHARACTERISTICS:
• Age
• 26 and over (age 18 to 25 allowed provided there is closure of the epiphyses on radiography)
• Performance status
• ECOG 0-1
• Life expectancy
• More than 6 months
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• No bleeding disorders
• No hemorrhage ≥ grade 2 within the past 12 months
• Hepatic
• Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• Alkaline phosphatase ≤ 2.5 times ULN
• ALT and/or AST ≤ 2.5 times ULN
• Albumin ≥ 3.2 g/dL
• PT/PTT ≤ 1.5 times ULN
• INR ≤ 1.5
• Renal
• Creatinine ≤ 1.5 times ULN OR
• Creatinine clearance ≥ 60 mL/min
• Cardiovascular
• QTc ≤ 460 msec by ECG
• No unstable angina within the past 6 months
• No decompensated congestive heart failure within the past 6 months
• No myocardial infarction within the past 6 months
• No serious cardiac arrhythmias or conduction abnormalities, including any history of recurrent ventricular arrhythmia, within the past 6 months
• No cardiomyopathy
• No history of syncope associated with arrhythmia
• No uncontrolled hypertension within the past 3 weeks, defined as systolic blood pressure \> 150 mm Hg or diastolic blood pressure \> 90 mm Hg on ≥ 2 of 3 blood pressure readings taken ≥ 5 minutes apart
• No thrombotic cardiovascular events, including transient ischemic attacks, within the past 12 months
• Gastrointestinal
• Able to take oral medication
• No malabsorption syndromes
• No active gastrointestinal bleeding (hematemesis, hematochezia, or melena), unrelated to cancer, within the past 3 months
• No requirement for IV alimentation
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after study participation
• No active infection
• No uncontrolled diabetes
• No dementia, altered mental status, or uncontrolled psychiatric illness that would preclude giving informed consent or study compliance
• No other serious uncontrolled medical disorder that would preclude study participation
• No other active malignancy within the past 3 years except treated limited stage basal cell or squamous cell skin cancer or carcinoma in situ of the breast or cervix
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No prior exposure to mouse antibodies
• No prior vascular endothelial growth factor (VEGF) or VEGF-receptor targeted therapy
• No other prior antiangiogenic anticancer therapy, including thalidomide
• No concurrent prophylactic colony-stimulating factors (i.e., filgrastim \[G-CSF\] or sargramostim \[GM-CSF\])
• No concurrent immunotherapy
• Chemotherapy
• Prior chemotherapy allowed provided patient received only a first-line platinum-based chemotherapy regimen with or without systemic consolidation chemotherapy
• At least 3 weeks since prior chemotherapy and recovered (excluding alopecia)
• No concurrent chemotherapy
• Endocrine therapy
• At least 3 weeks since prior hormonal therapy for ovarian cancer and recovered
• Concurrent hormone replacement therapy allowed
• No concurrent chronic oral or IV corticosteroids
• No concurrent hormonal therapy, including tamoxifen
• Radiotherapy
• No concurrent radiotherapy
• Surgery
• More than 4 weeks since prior major surgical procedure
• No prior gastric resection
• Other
• More than 3 weeks since prior investigational therapy
• More than 4 weeks since prior major medical interference with the peritoneum or pleura
• More than 3 months since prior treatment for active ulcer disease
• No prior consolidation intraperitoneal therapy using cytotoxic agents for ovarian cancer
• No concurrent antiarrhythmics
• * Beta blockers or calcium channel blockers used for other indications allowed
• No concurrent grapefruit juice
• No concurrent therapeutic anticoagulant therapy or chronic daily aspirin \> 325 mg/day
• * Concurrent low-dose anticoagulants for maintenance of central venous access allowed
• No other concurrent experimental or anticancer therapy for the primary disease